Atlas Trials

Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal Cancers

Clinical trial NCT02777710 · COMPLETED

Trial details

NCT number
NCT02777710
Sponsor
Centre Leon Berard
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Colorectal CancerPancreatic CancerMetastatic CancerAdvanced Cancer
Start date
2016-06-01
Primary completion
2019-11-01
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.